Biocytogen/Eucure Biopharma’s YH001 (Anti-CTLA-4 Monoclonal Antibody) Approved for Phase II Multi-Regional Clinical Trial by China National Medical Products Administration
BEIJING, November 9, 2021 - Eucure Biopharma, a wholly owned subsidiary of Biocytogen dedicated to developing proprietary antibody drugs, announced that the China National Medical Products Administration…
Read more
Biocytogen/Eucure Biopharma’s YH003 (Anti-CD40 Monoclonal Antibody) Approved for Phase II Multi-Regional Clinical Trial by China National Medical Products Administration
BEIJING, November 2, 2021 - Eucure Biopharma, a wholly owned subsidiary of Biocytogen dedicated to developing proprietary antibody drugs, announced that the China National Medical Products Administration…
Read more
Eucure Biopharma, a Subsidiary of Biocytogen, and TRACON Pharmaceuticals Announce Partnership for Development of Clinical Stage CTLA-4 Antibody YH001
YH001 is a potential best-in-class CTLA-4 antibody with enhanced ADCC and CDC effector functions YH001 is currently being dosed in multiple Phase 1 oncology trials…
Read more
Biocytogen Announces Collaboration With Envigo To Distribute the B-NDG Triple Immunodeficient and Humanizable Mouse Model
BEIJING and BOSTON, Sept. 28, 2021 /PRNewswire/ -- Biocytogen announces a collaboration with Envigo, a global organization offering the broadest range of research models and related services. The two companies…
Read more
Eucure Biopharma to Present Clinical Data Presentations of YH001 (Anti-CTLA-4 mAb) in the Treatment of Advanced Solid Tumors at 2021 CSCO Meeting
BEIJING, September 25-29, 2021 — The 24th National Conference on clinical oncology and the 2021 CSCO annual conference will be held online and offline in…
Read more
Biocytogen/Eucure Biopharma’s CTLA-4 and CD40 mAbs Approved for Phase II Clinical Trials by the FDA
BOSTON and BEIJING, July 6, 2021 --Eucure Biopharma, a wholly owned subsidiary of Biocytogen dedicated to developing antibody drugs with independent intellectual property rights, announced…
Read more
Biocytogen Completes a New Round of Financing Totaling Tens of Millions of Dollars
BEIJING and BOSTON, June 22, 2021- Biocytogen, an international biotechnology company focused on antibody drug research and development using innovative genetically engineered animal models, today…
Read more
Eucure Biopharma to Present Findings From Anti-CD40 and Anti-CTLA-4 mAb Clinical Trials at the 2021 ASCO Meeting
BEIJING and BOSTON, June 1, 2021 /PRNewswire/ -- Eucure Biopharma will present findings from two Phase I clinical trials at the 2021 American Society of Clinical Oncology (ASCO) Annual…
Read more
Biocytogen Best Research Paper Award commends typhoid toxin and potential peptide therapy research
Boston, May 27, 2021, adapted from Cornell Chronicle, Graduate students and postdoctoral researchers in the Department of Microbiology and Immunology from Cornell University faced stiff…
Read more
Eucure Biopharma Announces Breakthrough Phase I Results for Anti-CTLA-4 Therapy in Combination with Junshi Biosciences’ Anti-PD-1
BOSTON and BEIJING, March 22, 2021 /PRNewswire/ -- Eucure Biopharma, a subsidiary of Biocytogen focused on developing proprietary immuno-oncology antibodies, announced that its anti-CTLA-4 antibody (YH001), in combination with Junshi…
Read more